Filing Flows › Regenxbio (RGNX) › R&D spending
Regenxbio (RGNX) R&D spending by quarter
Regenxbio's R&D spending was $56.1M in Q2 2026 (second quarter 2026), -2% from Q1 2026. Over the last 6 quarters it ranged from $53.1M (Q1 2025) to $59.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $56.1M | -2% | -6% |
| Q1 2026 | $57.3M | -4% | +8% |
| Q4 2025 | $59.6M | +6% | — |
| Q3 2025 | $56.1M | -6% | — |
| Q2 2025 | $59.5M | +12% | — |
| Q1 2025 | $53.1M | — | — |
Q2 2026 at a glance
Regenxbio, Q2 2026: revenue $108M (+406% year over year), operating margin 27.1%, net earnings $22.7M, operating cash flow −$62.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Regenxbio's R&D spending?
Regenxbio's R&D spending was $56.1M in Q2 2026 (second quarter 2026), -2% from Q1 2026.
How has Regenxbio's R&D spending changed?
Over the last 6 quarters it ranged from $53.1M (Q1 2025) to $59.6M (Q4 2025).